UroGen filing shows Paradigm holds 1.7M shares

UroGen Pharma Ltd. reports passive beneficial ownership disclosures by Paradigm BioCapital entities and Senai Asefaw as of 03/31/2026.

Rhea-AI Filing Summary

UroGen Pharma Ltd. reports passive beneficial ownership disclosures by Paradigm BioCapital entities and Senai Asefaw as of 03/31/2026. The filing lists specific share holdings, including 1,703,949 shares reported for Paradigm BioCapital Advisors and related parties and 1,501,473 shares for Paradigm BioCapital International Fund Ltd.

The filing states these holdings represent 3.5% and 3.1% of the class respectively, calculated from 48,708,280 Ordinary Shares outstanding as of 03/31/2026 per the issuer's Form 10-Q. Reporting persons disclaim ownership beyond the shares directly held.

Insights

Institutional Ownership Analyst

Filing documents passive stakes: Paradigm entities hold mid-single-digit positions.

The statement lists exact holdings: 1,703,949 shares for Paradigm BioCapital Advisors/Adviser GP and Senai Asefaw, and 1,501,473 shares for the Fund. Percentages are tied to 03/31/2026 outstanding share count of 48,708,280.

These entries are passive beneficial-ownership disclosures under Schedule 13G/A; the filing preserves disclaimers of ownership beyond reported positions. Subsequent filings would show any changes to these positions.

Corporate Governance Specialist

Ownership attribution clarifies manager/vehicle relationships and voting/dispositive powers.

The filing explains that the Adviser manages the Fund and accounts, the Adviser GP is the general partner, and Senai Asefaw is the managing member; voting and dispositive power counts are listed per reporting person.

Document notes all percentages use the issuer's reported outstanding shares as of 03/31/2026; any governance implications depend on future changes to holdings or disclosures.

Key Figures

Outstanding shares: 48,708,280 shares Paradigm BioCapital Advisors holdings: 1,703,949 shares Paradigm BioCapital International Fund holdings: 1,501,473 shares +2 more

5 metrics

Outstanding shares 48,708,280 shares as of 03/31/2026 per issuer Form 10-Q

Paradigm BioCapital Advisors holdings 1,703,949 shares reported as of 03/31/2026

Paradigm BioCapital International Fund holdings 1,501,473 shares reported as of 03/31/2026

Percent of class — Paradigm Advisors 3.5% calculated from 48,708,280 shares outstanding as of 03/31/2026

Percent of class — Fund 3.1% calculated from 48,708,280 shares outstanding as of 03/31/2026

Key Terms

beneficially own, sole dispositive power, Schedule 13G/A

3 terms

beneficially own regulatory

"The Fund and one or more separately managed accounts managed by the Adviser directly beneficially own the Ordinary Shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole dispositive power regulatory

"7 | Sole Dispositive Power 1,703,949.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G/A regulatory

"This is filed by the following (the "Reporting Persons"): ... Schedule 13G/A"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:25 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

UroGen Pharma Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.01 per share

(Title of Class of Securities)

M96088105

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): M96088105

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,703,949.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,703,949.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,703,949.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): M96088105

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,703,949.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,703,949.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,703,949.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: limited liability company

SCHEDULE 13G

CUSIP Number(s): M96088105

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,703,949.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,703,949.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,703,949.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): M96088105

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,501,473.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,501,473.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,501,473.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.1 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: UroGen Pharma Ltd.
(b)	Address of issuer's principal executive offices: 400 Alexander Park Drive, Princeton, NJ 08540
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Ordinary Shares reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Ordinary Shares directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Ordinary Shares other than the Ordinary Shares directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 520 Fifth Avenue, 23rd Floor, New York, NY 10036.
(c)	Citizenship: For citizenship or place of organization see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Ordinary Shares, par value NIS 0.01 per share
(e)	CUSIP No.: M96088105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on March 31, 2026, the Date of Event which requires the filing of this Schedule 13G.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 48,708,280 Ordinary Shares outstanding as of March 31, 2026, as reported by the Issuer in its Form 10-Q filed with the SEC on May 6, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	05/15/2026

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	05/15/2026

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	05/15/2026

Paradigm BioCapital International Fund Ltd.

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	05/15/2026